Cutaneous T-cell lymphoma (CTCL) is a type of T-cell lymphoma that mostly affects the skin however it may also affect the blood, lymph nodes, and internal organs of the patient. It is divided into two more types that are fungoides and mycosis. Between these two; Cutaneous T-cell lymphoma (CTCL) is a rare blood disease that affects the immune system and skin lesions are caused due to the genetic mutations develop by Cutaneous T-cell lymphoma (CTCL).
New research by a dermatologist Robert Gniadecki finds that cancer cells that are present in the skin lesions with T cell lymphoma do not originate from the skin of the patients but the blood. It is discovered by taking the tissues of skin lesions of those patients who are facing cutaneous T-cell lymphoma (CTCL), a type of T-cell lymphoma.
This discovery is helpful to find more treatment methods for rare blood disease. The researchers at the University of Alberta have discovered more advanced treatment methods against a rare blood disease. All these attempts are made to get rid of cancer cells from the skin. The complete results of this study can be reached out in the journal “Blood”.
Read more-FDA Approves Vaccine Against Possible H5N1 Influenza Pandemic in the US
The director of the Division of Dermatology and a member of the Cancer Research Institute of Northern Alberta, Robert Gniadecki believes that it is better to start treatment when the malignant clones are formed in the blood and should not wait for the cancer cells to appear as skin lesions.
The presence of just noticeable lesions shows that a large quantity of cancer cells is already present in the blood. It is more convenient to kill the cells that grow in the skin because these cells are immature enough to be killed easily.
While the malignant clone cells present in the blood can’t be killed easily because these cells are less variable. If the treatment is started in the early stage there are more expectations of a person’s normal life.
Robert Gniadecki is also running his work with the Alberta Machine Intelligence Institute (Amii). Gniadecki wants to identify the biomarkers in the blood that can help researchers to know how the disease develops. For this purpose, Gniadecki passes the genetic information from the samples with the help of a machine learning program.
It’s necessary to start the treatment from day one when the disease is diagnosed. Because people have a lack of knowledge about Cutaneous T-cell lymphoma (CTCL). Usually, it doesn’t recognize early because CTCL often looks like a skin condition like psoriasis or eczema, the test for skin cancer and blood tests usually do not show the cancer cells.
Gniadecki finds that Cutaneous T-cell lymphoma (CTCL) is progressive and researchers are still unable to find the best cure against it. This is not an infection of the skin or psoriasis but cancer that is growing in the skin.
The researchers want a cure against it as it is the major medical need. The current study is helpful in a way to find new treatment methods against Cutaneous T-cell lymphoma (CTCL), a rare blood disease.
